← Leaderboards
Dean C Crick
Colorado State University-Fort Collins
$6,993,235
Attributed
$6,993,235
Total exposure
7
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $597.7K · FY2005–21$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$6,993,235 · 7
By mechanism
R01$5,240,185 · 2
U54$899,137 · 1
R21$407,645 · 1
R56$320,260 · 1
P01$114,008 · 1
R13$12,000 · 1
Top collaborators
No co-investigators on record.
Most similar at Colorado State University-Fort Collins
Same institution · by research overlap
- Susan L. Baldwin$5,451,001
- James H Naismith$554,601
Others in their field
Top investigators on “Mycobacterium Tuberculosis”
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$267,251,837
- Constance Ann Benson · University Of California, San Diego$150,079,712
- Kevin Urdahl · Seattle Children'S Hospital$86,597,961
- David Alland · Rutgers Biomedical And Health Sciences$70,943,567
- Sarah Fortune · Harvard School Of Public Health$51,119,645
- William Robert Jacobs · Albert Einstein College Of Medicine$43,123,310
Research focus
Mycobacterium TuberculosisAntitubercular AgentsLeadDrug ResistanceInhibitor/AntagonistDrug DevelopmentTuberculosisPropertyTuberculosis DrugsPathogenAnabolismEnzymesInterestOrganismPharmaceutical PreparationsMycobacterialGrowthBioterrorismIncidenceBiological AvailabilityEvaluationListeria MonocytogenesGram-Positive BacteriaHigh Throughput Screening
Grant awards (27)
Colorado Mycobacteria Conference: Focus on NTM$12,000
R13 · FY2021 · AI · contact PI
Menaquinone Biosynthesis: A Drug Target in Gram-Positive Bacteria$420,437
R01 · FY2019 · AI · contact PI
Menaquinone Biosynthesis: A Drug Target in Gram-Positive Bacteria$420,351
R01 · FY2018 · AI · contact PI
Menaquinone Biosynthesis: A Drug Target in Gram-Positive Bacteria$419,611
R01 · FY2017 · AI · contact PI
Menaquinone Biosynthesis: A Drug Target in Gram-Positive Bacteria$420,643
R01 · FY2016 · AI · contact PI
Unraveling the Origin of Pyrazinamide's Synergy with other anti-TB Drugs$177,035
R21 · FY2016 · AI · contact PI
Unraveling the Origin of Pyrazinamide's Synergy with other anti-TB Drugs$230,610
R21 · FY2015 · AI · contact PI
Menaquinone Biosynthesis: A Drug Target in Gram-Positive Bacteria$222,155
R01 · FY2015 · AI · contact PI
HTS assays for the methylerythritol-4-phosphate pathway$375,497
R01 · FY2014 · AI · contact PI
HTS assays for the methylerythritol-4-phosphate pathway$352,917
R01 · FY2013 · AI · contact PI
HTS assays for the methylerythritol-4-phosphate pathway$399,241
R01 · FY2012 · AI · contact PI
Menaquinone biosynthesis:a drug target in Gram-positive bacteria$330,594
R01 · FY2011 · AI · contact PI
Menaquinone biosynthesis:a drug target in Gram-positive bacteria$333,745
R01 · FY2010 · AI · contact PI
Menaquinone biosynthesis:a drug target in Gram-positive bacteria$336,931
R01 · FY2009 · AI · contact PI
Isoprenoid Biosynthesis: A Target for Drugs Against Category A-C Pathogens$238,746
U54 · FY2008 · AI · contact PI
Menaquinone biosynthesis:a drug target in Gram-positive bacteria$221,413
R01 · FY2008 · AI · contact PI
Menaquinone biosynthesis: a drug target in Gram-positive bacteria$320,260
R56 · FY2007 · AI · contact PI
Isoprenoid Biosynthesis: A Target for Drugs Against Category A-C Pathogens$266,008
U54 · FY2007 · AI · contact PI
Isoprenoid Biosynthesis: A Target for Drugs Against Category A-C Pathogens$197,585
U54 · FY2006 · AI · contact PI
Isoprenoid Biosynthesis: A Target for Drugs Against Category A-C Pathogens$196,798
U54 · FY2005 · AI
Sterol/Hopanoid Biosynthesis: An Anti-TB Drug Target$243,850
R01 · FY2004 · AI
Sterol/Hopanoid Biosynthesis: An Anti-TB Drug Target$243,850
R01 · FY2003 · AI
Sterol/Hopanoid Biosynthesis: An Anti-TB Drug Target$245,200
R01 · FY2002 · AI
DRUGS DIRECTED AGAINST ISOPRENOID BIOSYNTHESIS$0
P01 · FY2002 · AI
Sterol/Hopanoid Biosynthesis: An Anti-TB Drug Target$253,750
R01 · FY2001 · AI
DRUGS DIRECTED AGAINST ISOPRENOID BIOSYNTHESIS$0
P01 · FY2001 · AI
DRUGS DIRECTED AGAINST ISOPRENOID BIOSYNTHESIS$114,008
P01 · FY2000 · AI